Pharmaceutical companies have pledged to share surveillance data on new anti-microbial medicines, such as antibiotics, in a new register launched to combat anti-microbial resistance (AMR). This, they say, will provide “an early warning system for one of the greatest public health threats we face”.
The initiative launched on 21 June by Vivli, a non-profit clinical research data sharing organisation, will enable scientists worldwide to access data on epidemiological, physical and genetic characteristics of organisms and their resistance to various antibiotics, reports SciDev.Net.
Deaths attributed to anti-microbial resistance in 2019 were on a par with those linked to HIV and malaria combined, with sub-Saharan Africa having the highest burden of AMR, according to a study published in The Lancet early this year.
Anti-microbial resistance was linked directly to an estimated 1.27m deaths globally, while HIV/Aids and malaria directly accounted for 860,000 and 640,000 deaths respectively. Low- and middle-income countries are the worst affected.
Rebecca Li, executive director of Vivli, told SciDev.Net that the register provides centralised access to high-quality industry data that will aid critical decision-making to curb anti-microbial resistance.
According to Vivli, Pfizer, GSK, Johnson & Johnson, Merck, Paratek Pharmaceuticals, and Venatorx Pharmaceuticals are some of the pharmaceutical companies that have committed to sharing their data on the AMR register, which is supported by a seed grant from UK-based health research charity Wellcome.
“Sub-Saharan Africa has some of the least developed AMR surveillance systems in the world,” said Karen Bett, policy manager for data equity and inclusion at the UN’s Global Partnership for Sustainable Development Data. “Such a system will enable Africa to catch up but also give a true picture of the status of AMR on the continent.”
Bett added that the system will provide a foundation for a better understanding of the spread of anti-microbial resistance, especially in sub-Saharan Africa and Southeast Asia, which have the least developed surveillance coverage compared with high-income regions such as North America and Europe.
Marc Mendelson, chair of the AMR Register Scientific Advisory Board and a professor of infectious disease at the University of Cape Town, said biopharmaceutical company data was a “vital missing link in anti-microbial resistance surveillance”.
“Our understanding of how to control anti-microbial resistant infections and how best to protect human health hinges on better access to surveillance data,” he said.
“Now, with the AMR Register we have an early warning system for one of the greatest public health threats we face.”
Henry Kajumbula, a member of the scientific advisory group guiding the register and chair of the department of microbiology at Makerere University in Uganda, told SciDev.Net: “This is particularly important as it will enable scientists who are generating data locally to have a basis for comparison and those that have limitations in generating their own data to have a dataset to begin with.”
Kajumbula said that the register will allow scientists to build skills in data analysis that could be an evidence to support application for collaborative funding.
“The value to public health officials, multi-lateral organisations and researchers globally are to identify outbreaks, predict future trends in AMR, inform policy and identify new resistance mechanisms. It is our hope that this data would be used to proactively address our next emerging pandemic,” Kajumbula added.
The Lancet article – The Overlooked Pandemic
SciDev.Net article – Pharma companies to share data on antimicrobial resistance (Open access)
See more from MedicalBrief archives:
Stories from the frontlines of antimicrobial resistance during COVID-19
MPs want patent laws changed to address antimicrobial resistance
WHO fight against antimicrobial resistance
Wound dressing to counter antimicrobial resistance